Redcare Pharmacy: A Dual Regulatory Boost That Could Reshape the Second Half
12.06.2026 - 16:26:38 | boerse-global.de
The German pharmacy sector is undergoing its most significant policy shift in years, and Redcare Pharmacy sits squarely in the crosshairs of two separate regulatory changes that analysts believe could lift margins and simplify patient access. Yet the stock remains pinned near multi-month lows, caught between operational progress and the mechanical drag of an index reshuffle.
On Friday, the Bundesrat gave its final approval to the long-debated pharmacy reform, expanding the scope of what pharmacists can do. They will now be permitted to administer vaccinations using inactivated vaccines and to perform blood draws for medication monitoring. For online operators, the most consequential change concerns chronic-care patients: the smallest available pack size of a maintenance drug can now be dispensed without a fresh prescription, provided ongoing therapy is not interrupted. The move lowers the friction for digital medication management and plays directly into Redcare’s strategic focus on the chronic-disease segment.
Separately, the Bundeskabinett has locked in a multi-step increase in the fixed dispensing fee, the so-called Fixum. From July 2026, the remuneration per prescription pack will rise to €9.00 from the current €8.35, followed by a further jump to €9.50 in January 2027. Analysts estimate the initial increase alone will boost gross profit per pack by roughly 13%. Redcare has made expanding its prescription-drug business a priority, targeting revenues of more than €670 million in that division this year.
The company’s digital infrastructure is also getting a technological upgrade. The national health agency, gematik, is finalising a new module that verifies a patient’s presence when an e-prescription is redeemed, a feature designed to simplify the process. Redcare has already integrated solutions that allow customers to dispense with PIN entry, helping to push its active user base past the 14-million mark.
Should investors sell immediately? Or is it worth buying Redcare Pharmacy?
Yet the share price has been unable to shake off a persistent downtrend. The stock changed hands near €49.50 on Friday, just below its 100-day moving average of €49.65. A sustained break above that level would provide a technical signal that the direction may be shifting. Even so, the year-to-date decline stands at roughly 26%, and the 52-week high of €112.10 remains more than 55% away.
Adding to near-term pressure is the impending demotion from the MDAX to the SDAX in June. Passive investment funds that track the mid-cap index will be forced to adjust their holdings, triggering a wave of mechanical selling that has already pushed the shares into a range between €48 and €49. Management has stressed that the index shift has no bearing on the underlying business, but the short-term technical overhang is unmistakable.
Operationally, Redcare appears to be firing on several cylinders. The active Rx customer base has doubled recently, with much of the growth coming from chronic-care patients drawn to digital convenience. The company holds a leading position in five of the seven European markets where it operates, bolstered by an e-prescription infrastructure that positions it well for the new regulatory environment.
Redcare Pharmacy at a turning point? This analysis reveals what investors need to know now.
The full-year outlook remains intact. Management has reiterated its forecast for group revenue growth of 13% to 15% in 2026, with an adjusted EBITDA margin of at least 2.5%. The higher dispensing fees will begin to feed through fully in the third quarter, just as investors turn their attention to the half-year report due in July. Whether the combined impact of the pharmacy reform and the fee increases can lift the stock out of its year-long rut will depend on how quickly these policy changes translate into a measurable shift in patient behaviour towards digital channels.
Ad
Redcare Pharmacy Stock: New Analysis - 12 June
Fresh Redcare Pharmacy information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
